Clinical Report: Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications

Overview

This report evaluates the potential risk of eating disorders linked to GLP-1 medications, highlighting that 1.28% of users may develop such disorders. The findings underscore the need for screening and further research in this area.

Background

The increasing use of GLP-1 receptor agonists for weight management raises concerns about their association with eating disorders. As these medications become more prevalent, understanding their psychological impacts is crucial for patient safety. Current research on this topic is limited, necessitating further investigation.

Data Highlights

Out of over 60,000 individuals taking GLP-1 medications, 1.28% were diagnosed with an eating disorder within two years.

Key Findings

• 1.28% of GLP-1 users were diagnosed with an eating disorder within two years.
• Potential for over 420,000 Americans to develop eating disorders if GLP-1 usage continues to rise.
• Current screening practices for eating disorders in patients prescribed GLP-1s are inadequate.
• There is a mechanistic overlap in the biology of obesity and anorexia that warrants further exploration.
• Regulatory bodies are currently unprepared for the potential increase in eating disorders associated with GLP-1 medications.

Clinical Implications

Healthcare providers should implement routine screening for eating disorders in patients prescribed GLP-1 medications. Increased awareness and research are essential to mitigate potential risks and improve patient outcomes.

Conclusion

The association between GLP-1 medications and eating disorders necessitates careful monitoring and further research to ensure patient safety and effective treatment strategies.

References

1. Amanda Banks, NEJM Perspective, 2023 -- Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications
2. The New Gastroenterologist — Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
3. conexiant — GLP-1 Drugs Linked to GI Effects, Uncertain Signals
4. The New Gastroenterologist — Recent Findings Link GLP-1 Receptor Agonists to Increased Risk of GERD
5. the asco post — Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
6. Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
7. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications
8. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial - PMC
9. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026 - PMC